SCHEMBL5451260

SCHEMBL5451260

NC(=O)c1c(NC(=O)Nc2ccc(OC(F)(F)F)cc2)sc2c(Br)c(O)ccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 6/20 0.51
FAAH O00519 2/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
STING1 Q86WV6 1/20 0.41
P2RY1 P47900 2/20 0.40
EPHX1 P07099 2/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
TP53 P04637 1/20 0.39
CASP3 P42574 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5466938 0.85 CA12 (0.44) NPC1RAB9AMEN1MAPTKMT2A
SCHEMBL5460123 0.80 EPHX2 (0.52) EPHX2FAAHNPC1RAB9ASTING1
SCHEMBL5453506 0.80 MAPT (0.45) EPHX2NPC1RAB9AMEN1MAPT
SCHEMBL5455851 0.75 STING1 (0.40) NPC1RAB9ASTING1MEN1MAPT
SCHEMBL5455848 0.73 KMT2A (0.43) NPC1RAB9AMEN1MAPTKMT2A
SCHEMBL5455812 0.73 MAPT (0.58) EPHX2NPC1RAB9AMEN1MAPT
SCHEMBL11555827 0.71 EPHX2 (1.00) EPHX2FAAHNPC1RAB9ASTING1
SCHEMBL19353262 0.70 KMT2A (0.38) NPC1RAB9AMEN1MAPTKMT2A
SCHEMBL5448926 0.70 FLT3 (0.47) NPC1RAB9AMEN1MAPTKMT2A
SCHEMBL5452297 0.69 TNIK (0.54) EPHX2FAAHEPHX1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 EPHX2 3325/4885FAAH 3341/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.